Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

Gilead Sciences Announces Third Quarter 2022 Financial Results

Business Wire October 27, 2022

Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of Comorbidities

Business Wire October 24, 2022

Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers

Business Wire October 20, 2022

Gilead Presents Real-World and Long-Term Data From HIV Research Programs at HIV Glasgow 2022

Business Wire October 18, 2022

Kite's Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Business Wire October 17, 2022

Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies

Business Wire October 17, 2022

Gilead Sciences to Release Third Quarter 2022 Financial Results on Thursday, October 27, 2022

Business Wire October 13, 2022

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead's Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer

Business Wire October 11, 2022

Kingmakers of Oakland Aims to Improve the Lives of Young Black Men

Accesswire October 6, 2022

Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product

Business Wire October 3, 2022

Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines

Business Wire September 22, 2022

Gilead Sciences Completes Acquisition of MiroBio

Business Wire September 20, 2022

Kite's CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Business Wire September 16, 2022

CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19

Business Wire September 16, 2022

WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline

Business Wire September 15, 2022

Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity

Business Wire September 13, 2022

Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study

Business Wire September 7, 2022

Kite's CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)

Business Wire September 6, 2022

New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy® Regardless of Their HER2 Status

Business Wire September 4, 2022

Gilead Sciences to Present at Upcoming Investor Conferences

Business Wire August 29, 2022